Adiso Therapeutics Announces Publication of Compelling Preclinical Research on ADS051, a First-in-Class Oral, Gut-restricted, Small Molecule Modulator of Neutrophil Trafficking and Activation
CBS17.com,
Company plans to initiate Phase 2a dose ranging clinical trial for patients with ulcerative colitis in 4Q 2023 CONCORD, Mass.…